C1Add image
CJC-1295 (no DAC)
PerformanceSingleAlso known as: MOD GRF 1-29, Modified GRF
A growth-hormone-releasing hormone analog studied for performance contexts.
Half-life
0.5 h
Common dose
70 – 140 mcg
Dosing frequency
Daily
Administration
Subcutaneous
How it works
CJC-1295 No DAC binds the GHRH receptor in the pituitary, triggering acute GH release. Without the DAC modification, its half-life is ~30 minutes, producing a sharp pulse rather than sustained elevation. Frequently paired with a GHRP (ipamorelin, GHRP-2) for synergistic release.
Protocol notes
Typical research protocols use 100–200 mcg subcutaneously 1–3 times daily, usually pre-bed and post-workout. Cycles of 8–16 weeks. Almost always stacked with a GHRP — most commonly Ipamorelin.
Reported side effects
Injection-site reactions, transient flushing, light-headedness, water retention, and mild numbness in extremities.
Additional research notes
GHRH analog. Usually dosed 100–200mcg per injection.